Abhimanyu Verma Sells 5,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

August 6, 2026 by InsiderTrades.com

Key Points

Chairman Jurgi Camblong sold 20,000 SOPHiA GENETICS shares at an average price of $6.92, generating $138,400. The transaction was made under a pre-arranged Rule 10b5-1 plan and reduced his direct holdings by 0.57% to 3.47 million shares.
SOPHiA GENETICS reported quarterly revenue of $23.31 million, exceeding estimates, but its $0.26-per-share loss was wider than expected. The company continues to face significant profitability challenges, including a negative net margin of 93.86%.
Analyst sentiment remains mixed, with an overall “Hold” consensus and a $10 average price target. HC Wainwright and BTIG raised their targets and maintained Buy ratings, while the company also increased its 2026 revenue outlook to $94 million–$96 million.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) CTO Abhimanyu Verma sold 5,000 shares of the company's stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $6.95, for a total value of $34,750.00. Following the completion of the transaction, the chief technology officer directly owned 187,171 shares of the company's stock, valued at approximately $1,300,838.45. This represents a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Abhimanyu Verma also recently made the following trade(s):

On Monday, July 6th, Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.10, for a total value of $26,953.50.
On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.51, for a total value of $38,261.44.

SOPHiA GENETICS Trading Down 7.9%

NASDAQ SOPH opened at $6.30 on Thursday. The business's fifty day moving average is $5.54 and its 200-day moving average is $5.12. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90. The stock has a market capitalization of $528.51 million, a price-to-earnings ratio of -5.48 and a beta of 0.96. SOPHiA GENETICS SA has a one year low of $2.96 and a one year high of $7.21.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 153.15%. The company had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. Equities research analysts predict that SOPHiA GENETICS SA will post -0.58 EPS for the current year.

Institutional Investors Weigh In On SOPHiA GENETICS

Large investors have recently added to or reduced their stakes in the business. Perkins Capital Management Inc. purchased a new position in SOPHiA GENETICS during the fourth quarter worth about $49,000. Squarepoint Ops LLC bought a new stake in shares of SOPHiA GENETICS during the 3rd quarter valued at about $49,000. First Dallas Securities Inc. bought a new stake in shares of SOPHiA GENETICS during the 1st quarter valued at about $50,000. Quadrature Capital Ltd purchased a new position in shares of SOPHiA GENETICS during the fourth quarter worth about $54,000. Finally, XTX Topco Ltd bought a new position in shares of SOPHiA GENETICS in the fourth quarter worth approximately $55,000. Institutional investors own 31.59% of the company's stock.

Wall Street Analyst Weigh In

SOPH has been the subject of several research analyst reports. HC Wainwright raised their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a "buy" rating in a research note on Wednesday. Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. BTIG Research increased their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday. Finally, Zacks Research upgraded SOPHiA GENETICS to a "hold" rating in a research note on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, SOPHiA GENETICS presently has an average rating of "Hold" and an average target price of $10.00.

View Our Latest Analysis on SOPHiA GENETICS

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

Positive Sentiment: SOPHiA GENETICS raised its 2026 revenue outlook to $94 million–$96 million, above the approximately $93.4 million consensus estimate, implying 22%–24% year-over-year growth. Management also continues to target adjusted EBITDA breakeven by year-end. 2026 revenue outlook and EBITDA breakeven article
Positive Sentiment: The company announced a multi-year global collaboration with AstraZeneca to develop, validate and commercialize two companion diagnostics for precision-oncology therapies. The agreement could expand SOPH’s role in oncology testing and support longer-term revenue growth. AstraZeneca collaboration article
Positive Sentiment: HC Wainwright raised its price target from $12 to $14 and maintained a Buy rating, while BTIG lifted its target from $8 to $9 and also kept a Buy rating. The revisions indicate improving analyst confidence in SOPH’s growth outlook. Analyst price target updates
Positive Sentiment: Second-quarter revenue increased 27% year over year to $23.3 million, exceeding expectations of $21.7 million, while the adjusted EBITDA loss improved 27% to $8.8 million. Second-quarter 2026 results article
Neutral Sentiment: Chairman Jurgi Camblong, CTO Abhimanyu Verma and insider Zhenyu Xu collectively sold 35,000 shares for about $242,350 under pre-arranged Rule 10b5-1 plans. The sales reduced their holdings only modestly, limiting their signaling value.
Negative Sentiment: SOPH reported a quarterly loss of $0.26 per share, missing the $0.21-loss consensus estimate by $0.05. Net loss remained $22.4 million, and gross margin declined from the prior-year period, underscoring continuing profitability concerns. Quarterly earnings report

About SOPHiA GENETICS

(Get Free Report)

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.